"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically unfavourable mutation," according to Wolfgang Brueckl, MD, of t ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and Roche.

The monoclonal antibody, trastuzumab, is a targeted therapy that is effective in HER2-positive metastatic breast cancer as a single agent but is particularly effective in combination with ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

HER2 is a protein that allows breast cancer ... stopping them from accessing the hormones they need to multiply. monoclonal antibody drugs, such as trastuzumab or pertuzumab combining trastuzumab ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

The monoclonal antibody against HER2, trastuzumab (Herceptin), ® has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant ...

These investigators assessed the efficacy--or lack thereof--from HER-2 targeted therapies that were evaluated in relation to ERBB2 variants using a cancer genome screening project. Share on Facebook.

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...